EBI-031 is a humanized antibody inhibitor targeting IL-6. It is a non-steroidal anti-inflammatory inhibitor with excellent biological efficacy in treating eye diseases, such as non-infectious uveitis (NIU), retinal vascular diseases, and other conditions, including non-uveitic macular edema and diabetic macular edema.

EBI-031 demonstrates exceptional binding affinity to human IL-6 at site II or the gp130 contact site, with an affinity reaching pM levels, and effectively inhibits the signaling of IL-6 and the IL-6/sIL-6Rα complex. EBI-031 also exhibits good thermal stability, with its Fab fragment having a Tm of 76 ℃, and can be concentrated to over 100 mg/mL with negligible measurable aggregation.

EBI-031 (IVT) significantly extends the vitreal clearance half-life in a rabbit model, with a t 1/2 of approximately 10 days, compared to Aflibercept's half-life of about 6 days and Tocilizumab's of around 5 days.